



Ricardo Camposanto

Associate | San Francisco

Practice Areas

Intellectual Property

Contact

T: 202.469.3521

rcamposanto@axinn.com



[Download V-Card](#)

Ricardo Camposanto is an associate in Axinn's Intellectual Property group. His practice is focused on patent litigation, including service of clients in the fields of pharmaceuticals, medical devices, and wireless technologies. In addition to his extensive trial court experience, he has also practiced before the Federal and Fourth Circuits, Patent Trial and Appeals Board, and International Trade Commission. His practice further includes counseling services related to patent portfolio evaluation, drafting of licensing agreements and other contracts, and pro bono work related to local business disputes and Section 1983 civil rights litigation.

Ricardo graduated from the University of California, Berkeley in 2009 with a BA in Molecular and Cell Biology. He received his JD from the University of Virginia School of Law, where he served on the Editorial Board for the *Virginia Law Review* and worked in the Appellate Litigation Clinic. In 2014, he was a judicial extern to the Honorable Margaret M. Mann with the U.S. Bankruptcy Court, Southern District of California. He worked as a summer associate at Axinn in 2015.

Experience

- *Alcon Inc. v. Alembic Pharmaceuticals Ltd. et al.* (22-cv-00299, D. Del.). Represented Alembic Pharmaceuticals Ltd. and Alembic Pharmaceuticals Inc. in a case in which Alcon Inc. and Alcon Laboratories Inc. asserted two patents relating to Alembic's ANDA product, an ophthalmic solution containing olopatadine hydrochloride used to treat symptoms of ocular allergies.
- *Cosette Pharmaceuticals Inc. v. Azurity Pharmaceuticals Inc.* (23-cv-0018, D. Del.). Lead counsel to Cosette in a Hatch-Waxman suit against Azurity Pharmaceuticals Inc. involving Cosette's vancomycin hydrochloride product. Secured total victory and consent judgment on all six asserted patents.
- *Salix Pharmaceuticals Ltd. et al. v. Norwich Pharmaceuticals Inc.* (20-cv-00430, D. Del.). Represented Norwich Pharmaceuticals Inc. in a patent infringement action filed by Salix Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Bausch Health Ireland Ltd., and Alfasigma S.P.A. The suit sought to estop Norwich from gaining approval to market a rifaximin 550 mg tablet, a generic of Salix's Xifaxan[®]. Obtained judgment of invalidity on asserted claims, which halted the trading of plaintiff's parent company stock after it dropped more than 50% following the decision.
- *Boehringer Ingelheim Pharm., Inc. et al. v. Mankind Pharma et al.*, No. 18-cv-689-CFC (D. Del.). Obtained favorable settlement following expert discovery in patent litigation concerning multibillion-dollar treatments for diabetes. Took and defended multiple fact and expert depositions.
- *iCeutica Pty Ltd. et al. v. Novitium Pharma LLC*, No. 18-cv-599-CFC (D. Del.). Represented generic drug manufacturer Novitium in Hatch-Waxman litigation involving multiple patents directed to meloxicam (Vivlodex[®]). Secured dismissal of case based on noninfringement position resulting in favorable settlement for Novitium. Defended depositions of two 30(b)(6) corporate witnesses. Assisted with Markman briefing and sat second-chair at related hearing. Drafted discovery requests and responses, and led meet-and-confer calls with opposing counsel.
- *Omeros Corp. v. Par Sterile Products, LLC*, No. 15-cv-773-RGA (D. Del.). Represented generic drug manufacturer, Par, in Hatch-Waxman litigation involving multiple patents directed to ketorolac tromethamine/phenylephrine HCl (Omidria[®]). Secured favorable settlement for Par after three-day bench trial. Assisted with expert witness preparation, drafting of pre- and post-trial briefs, and written discovery.
- *Alcon Pharms. Ltd. et al. v. Par Pharm. Inc.*, No. 15-cv-7240 (D. N.J.). Represented generic drug manufacturer Par in Hatch-Waxman litigation involving multiple patents directed to ciprofloxacin/dexamethasone (Ciprodex[®]). Secured dismissal of case based on noninfringement position resulting in favorable settlement for Par. Served second-chair in both fact and expert witness depositions, and handled written discovery disputes.
- *Insys Therapeutics, Inc. v. Par Pharm., Inc.*, No. 17-cv-01078-LPS (D. Del.). Represented generic drug manufacturer Par in Hatch-Waxman litigation involving multiple patents directed to FDA-approved cannabinoid (Syndros[®]) used to treat anorexia in people with AIDS. Secured dismissal of case based on noninfringement position resulting in Par having the ability to launch upon approval of its ANDA product.

- *Purdue Pharma L.P. et al. v. Alvogen Pine Brook LLC, C.A. No. 15-0687-TBD* (consolidated) (D. Del.). Represented Alvogen in Hatch-Waxman patent litigation action against Purdue Pharma and Grünenthal GmbH involving abuse-deterrent hydrocodone bitartrate extended-release tablets marketed as Hysingla[®] ER. Case settled favorably on the eve of trial. Participated in the preparation of expert witnesses and identification of documents to support invalidity and noninfringement positions.
- *In re Certain UMTS and LTE Cellular Communication Modules and Products Containing the Same*, No. 337-TA-1240 (ITC). Defended Thales in investigation relating to alleged infringement of cellular communications patents.
- *AstraZeneca AB et al. v. Alembic Pharmaceuticals Limited et al.* (20-cv-202, D. Del.) Obtained a favorable settlement for Alembic in a Hatch-Waxman patent infringement action filed by AstraZeneca seeking to estop Alembic from obtaining approval to market an osimertinib oral tablet, a generic of AstraZeneca's Tagrisso[®], for the treatment of non-small cell lung cancer.

Honors

- *Best Lawyers, “Ones to Watch”* (2024 – 2025)
- Capital Pro Bono Honor Roll (High Honors, 2023)

Education

- JD – University of Virginia School of Law (2016)
- BA, Molecular and Cell Biology – University of California, Berkeley (2009)

Admissions

- District of Columbia
- Virginia
- California

Quotes

“Axinn is a great mix of people who are wicked smart, hard-working and just plain nice. The firm is responsive and always comes with thoughtful approaches to problems.”

